Published January 7, 2026
| Version v1
Journal article
Open
Comparative analysis of the Bulgarian national therapeutic guideline on breast cancer treatment with the NCCN, ASCO, and ESMO guidelines using the PICO methodology and its relevance to patient access
Authors/Creators
- 1. Medical University - Sofia, Sofia, Bulgaria
Description
Objectives: Patient-centric healthcare ecosystems prioritize personalized diagnostics and treatments based on high-quality evidence regarding health technologies. Pharmacotherapeutic guidelines are essential for providing evidence-based recommendations, enhancing patient safety, and aligning healthcare policies with early detection and rational drug use.
Methods: This study compares the Bulgarian pharmacotherapeutic guideline on breast cancer with the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), and European Society for Medical Oncology (ESMO) guidelines using the Population, Intervention, Comparison, and Outcome (PICO) methodology, assessing alignment in screening, pharmacotherapy, follow-up, outcomes, and shared decision-making.
Results: The results show that Bulgaria has a unified set of guidelines for tumor locations but lacks specific recommendations for screening and shared decision-making. While these guidelines align closely with international standards for breast cancer treatment, they do not offer guidance on follow-up, outcomes, or genomic profiling. Importantly, they incorporate new therapies before these are added to the Positive Drug List, thereby influencing regulatory decisions and patient access to treatments.
Conclusion: The Bulgarian pharmacotherapeutic guideline on breast cancer aligns with international standards but could be improved with respect to screening, early detection, therapy adherence, and shared decision-making. A structured classification for levels of evidence would also enhance the guidelines.
Files
PHAR_article_177816.pdf
Files
(305.5 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:e7dac0372f5dd4cc7ff643985e705d14
|
215.6 kB | Preview Download |
|
md5:2ffa91a4359179545208b9de3b9fb2e0
|
89.8 kB | Preview Download |
Additional details
References
- Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Petracci FE, Rugo HS, Saghir NSE, Arun BK (2024) Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline. JCO Global Oncology 10: e2300285. https://ascopubs.org/doi/10.1200/GO.23.00285
- ASCO (2020) Management of Male breast cancer, American Society of Clinical Oncology [Publication: February 14, 2020]. https://www.guidelinecentral.com/guideline/7265/pocket-guide/9255/ [Accessed on May 2025]
- ASCO (2021) Management of Hereditary Breast Cancer, American Society for Radiation Oncology, American Society of Clinical Oncology, Society of Surgical Oncology [Publication: August 03, 2021]. https://www.guidelinecentral.com/guideline/7598/pocket-guide/42024/ [Accessed on May 2025]
- ASCO (2025) ASCO Guideline Methodology https://www.asco.org/practice-patients/guidelines/guideline-methodology [Accessed on May 2025]
- ASCO Publications (2025) Journal of Clinical Oncology, An American Society of Clinical Oncology Journal. https://ascopubs.org/jco/special/guidelines [Accessed on May 2025]
- BG PhTher Guideline (2022) NCPR: Pharmacotherapeutic guideline on medical oncology. https://ncpr.bg/images/Naredbi_za_priemane_na_FTR/29.10.2019/Naredba_11_ot_2019_FTR_med_onkologia_priturka.pdf [Accessed on February 2022]
- Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL (2024) Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. Journal of Clinical Oncology 42(12): 1450–1453. https://doi.org/10.1200/JCO.24.00248
- Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio I, Zackrisson S, Senkus E (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 30(8): 1194–1220. https://doi.org/10.1093/annonc/mdz173
- ESMO (2025) ESMO Guidelines Committee (GLC) Standard Operating Procedures (SOPs) for ESMO Clinical Practice Guidelines (CPGs). https://www.esmo.org/guidelines [Accessed on May 2025]
- Freedman RA, Graff SL, Somerfield MR, Telli ML, Wolff AC, Giordano SH (2022) Adjuvant abemaciclib plus endocrine therapy in the treatment of high-risk early breast cancer: ASCO guideline rapid recommendation update Q and A. Journal of Clinical Oncology 18(7): 516–519. https://ascopubs.org/doi/10.1200/OP.22.00140
- Freedman RA, Graff SL, Somerfield MR, Telli ML, Wolff AC, Giordano SH (2024) Optimal adjuvant chemotherapy and targeted therapy for early breast cancer—cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update. Journal of Clinical Oncology 42(18): 2233–2235. https://ascopubs.org/doi/10.1200/JCO.24.00886
- Gao J, Calkins G, Birrer MJ, Dizon DS (2013) Achieving quality: Comparing recommendations for cancer care between NCCN and ESMO. Journal of Clinical Oncology 31: 6579. https://doi.org/10.1200/jco.2013.31.15_suppl.6579
- Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im S-A, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology 32(12): 1475–1495 [on behalf of the ESMO Guidelines Committee]. https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-metastatic-breast-cancer [Accessed on May 2025]
- Giordano SH, Freedman RA, Somerfield MR (2021) Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update. Journal of Clinical Oncology 40(3): 307–309. https://ascopubs.org/doi/10.1200/JCO.21.02677
- Huang X, Lin J, Demner-Fushman D (2006) Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annual Symposium Proceedings 2006: 359–363. https://pmc.ncbi.nlm.nih.gov/articles/PMC1839740/
- Karanyotova S, Topova B, Petrova E, Doychev P, Kapitanska E, Petrova G, Mitkova Z, Dimitrova M (2023) Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria. Frontiers in Public Health 11: 1073733. https://doi.org/10.3389/fpubh.2023.1073733
- Korde LA, Somerfield MR, Hershman DL (2022) Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update. Journal of Clinical Oncology 40(15): 1696–1698. https://ascopubs.org/doi/10.1200/JCO.22.00503
- Moy B, Wolff AC, Rumble RB, Allison KH, Carey LA (2023) Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncology Practice 19: 547–550. https://doi.org/10.1200/OP.23.00047
- Ministry of Health (2023) National Cancer Control Plan in the Republic of Bulgaria 2027, Ministry of Health in Republic of Bulgaria. https://www.mh.government.bg/bg/strategii/nacionalni-planove [Accessed on May 2025]
- NCCN (2025a) NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2025. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [Accessed on Sept 2025]
- NCCN (2025b) NCCN Guidelines, Ductal Carcinoma In Situ. https://www.nccn.org/guidelines/guidelines-detail?category=patients&id=30 [Accessed on May 2025]
- NCCN (2025c) NCCN Guidelines, Invasive Breast Cancer. https://www.nccn.org/guidelines/guidelines-detail?category=patients&id=16 [Accessed on May 2025]
- NCCN (2025d) NCCN, Development and Update of Guidelines. https://www.nccn.org/guidelines/guidelines-process/development-and-update-of-guidelines [Accessed on May 2025]
- Park of Health KU, Somerfield MR, Anne N, Brackstone M, Conlin AK, Couto HL, Dengel LT, Eisen A, Harvey BE, Hawley J, Kim JN, Lasebikan N, McDonald ES, Pradhan D, Shams S, Vega RM, Thompson AM, Torres MA (2025) Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. Journal of Clinical Oncology 43(14): 1720–1741. https://ascopubs.org/doi/10.1200/JCO-25-00099
- Paluch-Shimon S, Cardoso F, Partridge A, Abulkhair O, Azim Jr HA, Bianchi-Micheli G, Cardoso M-J, Curigliano G, Gelmon K, Harbeck N, Merschdorf J, Poortmans P, Pruneri G, Senkus E, Spanic T, Stearns V, Wengström Y, Peccatori F, Pagani O (2020) ESO-ESMO 4th International Concensus Guidelines for Breast Cancer in Young Women (BCY4). Annals of Oncology 31(6): 674–696. https://doi.org/10.1016/j.annonc.2020.03.284
- Ramírez-Morera A, Tristán M, Salazar-Vargas J, Ana Leonor , Rivera-Chavarría AL (2022) Effects of evidence-based clinical practice guidelines for breast cancer in health care quality improvements. A second systematic review. F1000 Research 11: 1213. https://doi.org/10.12688/f1000research.126126.2
- Seitaridou Y, Tsekov I, Kamusheva M, Dimitrova M, Petrova G (2021) Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. Expert Review of Pharmacoeconomics & Outcomes Research 22(2): 241–246. https://doi.org/10.1080/14737167.2021.1981134
- Sessa C, Balmaña J, Bober S, Cardoso M, Colombo N, Curigliano G, Domchek S, Evans D, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann J, Loibl S, Phillips K-A, Paluch-Shimon S (2023) Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Annals of Oncology 34(1): 33–47. https://doi.org/10.1016/j.annonc.2022.10.004
- Tung NM, Zakalik D, Somerfield MR (2021) Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update. Journal of Clinical Oncology 39(26): 2959–2961. https://ascopubs.org/doi/10.1200/JCO.21.01532
- Wilkinson L, Gathani T (2022) Understanding breast cancer as a global health concern. British Journal of Radiology 95(1130): 20211033. https://doi.org/10.1259/bjr.20211033
- World Health Organization (2017) WHO guide to the early diagnosis of cancer, 2017. https://www.who.int/publications/i/item/guide-to-cancer-early-diagnosis